


REFERENCES



REFERENCES

- Abrams D.I. and Guzman M., (2015). Cannabis in Cancer Care. *Clin pharmacol.*, 97(6): 575-586.
- Abdisa T., and Tagesu T., (2017). Review on Newcastle disease of poultry and its public health importance. *J. Vet. Sci. Technol.*, 8(441): 2.
- Abrams (2019). Should Oncologists Recommend Cannabis? Current treatment options in oncology, 20(7): 59.
- Abu Osman, Mamunur Rashid, Abdul Aziz, Rowshahul Habib and Rezaul karim (2011). *Asian Pac J Trop Biomed.*, 1(6): 448-451.
- Abu Sinna G., A. Y. Esmat, A. A. S. Al-Zahaby, N. A. Soliman, T. M. Ibrahim, (2003). Fractionation and characterization of *Cerastes cerastes cerastes* snake venom and the antitumor action of its lethal and nonlethal fractions, 42 (2) 207–215.
- Adjei A. M., Rameez H., and Al-Tae M. F. (2009). Disease virus, rituximab, and doxorubicin combination as anti-hematological malignancy therapy. *Oncolytic virotherapy*, 5: 27.
- Aktas E (1996). Ehrlich Asit Sıvısının L-Hücrelerinin Çoğalma Hızına Etkisi. Yüksek Lisans Tezi. İstanbul Üniversitesi Fen Bilimleri Enstitüsü. İstanbul, 2(8): 220-251.
- Akutsu M, Sugie K.I. and Saito K., (2017). Analysis of 62 synthetic cannabinoids by gas chromatography-mass spectrometry with photoionization. *Forensic Toxicol.*, 35: 94-103.
- Alexander A., Smith, P. F. and Rosengren, R. J. (2009). Cannabinoids in the treatment of cancer. *Cancer Letters*, 285: 6-12.
- Alfarouk K. O., Verduzco, D., Rauch, C., Muddathir, A. K., Adil, H. B., Elhassan, G. O., and Harguindey, S. (2014). Glycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer question. *Oncoscience*, 1(12): 777.
- Al-Shammari A., Salman M., Saihood Y., Yaseen, N., Raed K., Shaker H, and Duiach A. (2016). In vitro synergistic enhancement of Newcastle disease virus to 5-fluorouracil cytotoxicity against tumor cells. *Biomedicines*, 4(1): 3-24.
- American Cancer Society, (2014). Cancer Facts and Figures. *Lancet*. 371:(9625), 1695–1709.

- Amna HM, Elbagir NM and Gubara AA, (2011). The effect of cannabis sativa on certain enzymes of clinical significance in rats and men. *Journal of pharmacognosy issn.*, 1(2): 10-13.
- Amato R. J., Hawkins R. E., Kaufman H. L. (2010). "Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study," *Clinical Cancer Research*, 16 (22): 5539–5547.
- Antonia S. J., Seigne J., Diaz J. (2002). "Phase I trial of a B7-1(CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with meta-static renal cell carcinoma," *Journal of Urology*, 167(5): 1995–2000.
- Anaya D.A., G. Lahat, X. Wang, L. Xiao D. Tuvin P.W., Pisters D.C., and R.E. Pollock (2009). Establishing prognosis in retroperitoneal sarcoma: a new histology-based paradigm. *Ann Surg Oncol.*, 16(3): 667-675.
- Armstrong J.L. (2015). Exploiting Cannabinoid-Induced Cytotoxic Autophagy to Drive Melanoma Cell Death. *Journal of investigative dermatology*, 135(6):1629-1637.
- Asada H., Kishida T., Hirai H. (2018). "Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18. *Cancer therapy*, 322 (11): 233-302.
- Arlen P. M., Mohebtash M., Madan R. A., and Gulley J. L. (2009). "Promising novel immunotherapies and combinations for prostate cancer," *Future Oncology*, 5(2): 187–196.
- Aurisicchio L. and Ciliberto G. (2012). "Genetic cancer vaccines: current status and perspectives," *Expert Opinion on Biological Therapy*, 12(8): 1043–1058.
- Baars J. M., Van Riel, M. A. Cuesta, E. H. Jaspars, H. M. Pinedo, and A. J. M. van den Eertwegh (2002). "Metastasectomy and active specific immunotherapy for a large single melanoma metastasis," *Hepato-Gastroenterology*, 49 (45): 691–693.
- Badowski ME (2017). A review of oral cannabinoids and medical marijuana for the treatment of chemotherapy-induced nausea and vomiting: a focus on pharmacokinetic variability and pharmacodynamics. *Cancer Chemother Pharmacol.*, 33 (2): 210-322.
- Balarajan R. and E.D. Acheson (1984). Soft tissue sarcomas in agriculture and forestry workers. *J Epidemiol Community Health*, 38(2): 113-116.

- Balint Z, Holczinger L (1984). Changes in Lipoprotein Lipase Activity (LPLA) in Tumor Cells and Tissues in Mice Bearing Ehrlich Ascites Tumor. *Bull. Cancer*, 71(5): 100-121.
- Baram L. (2019). The Heterogeneity and Complexity of Cannabis Extracts as Antitumor Agents. *Oncotarget*, 10: 16.
- Barnes M.P. and Sativex (2006). Clinical Efficacy and Tolerability in the Treatment of Symptoms of Multiple Sclerosis and Neuropathic Pain. *Expert opinion*, 7: 607-615.
- Ben-Shabat S. (1998). An Entourage Effect: Inactive Endogenous Fatty Acid Glycerol Esters Enhance 2-Arachidonoyl-Glycerol Cannabinoid Activity. *European journal of pharmacology*, 353: 23-31.
- Berger M., Kreutz F. T., Horst J. L., Baldi A. C., and Koff W. J. (2007). “Phase I study with an autologous tumor cell vaccine for locally advanced or metastatic prostate cancer,” *Journal of Pharmacy & Pharmaceutical Sciences*, 10(2):144–152.
- Berd D., Maguire H. C., McCue P., and Mastrangelo M. J. (1990). “Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients,” *Journal of Clinical Oncology*, 8(11): 1858–1867.
- Berrington de Gonzalez, A.; Mahesh, M. and Kim, K. P. (2009). Projected cancer risks from computed tomographic scans performed in the United states. *arch. intern. Med*, 169 (22): 71 – 77.
- Bette M, Mandic R. (2014). Intraperitoneal oxidative stress as an oncolytic immunomodulator? *Oncoimmunology*, 3 (9): 47.
- Bhagirath D, Zhao X, West WW, Qiu F, Band H and Band V. (2015). Cell type of origin as well as genetic alterations contribute to breast cancer phenotypes, 6 (11): 18–30.
- Bhattacharyya A, Mandal D, Lahiry L, Sa G, and Das T (2004). Black tea protects immunocytes from tumor-induced apoptosis by changing Bcl-2/Bax ratio. *Cancer Lett.*, 209: 147–154
- Bielack S.S., B. Kempf-Bielack, G. Delling, G.U. Exner, S. Flege, K. Helmke, R. Kotz, M. Salzer-Kuntschik, M. Werner, W. Winkelmann, A. Zoubek, H. Jurgens, and K. Winkler (2002). Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. *J Clin Oncol*, 20(3): 776-90.

- Bijker M. S., Eeden S. J. F., Franken K. L., Melief C. J. M., Burg S. H., and Offringa (2008). "Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation," *European Journal of Immunology*, 38(4): 1033–1042.
- Bijker M. S., Franken K. L., Melief C. J. M., Offringa R., and S. H. van der Burg (2007). "CD8+ CTL Priming by Exact Peptide Epitopes in Incomplete Freund's Adjuvant Induces a Vanishing CTL Response, whereas Long Peptides Induce Sustained CTL Reactivity," *The Journal of Immunology*, 179(8): 5033–5040.
- Bifulco M, Laezza C, Portella G, Vitale M, Orlando P, DePetrocellis L (2001). Control by the endogenous cannabinoids system of ras oncogene-dependent tumor growth. *FASEB J*, 15: 274-357.
- Bild A. H., Yao G., Chang J. T., Wang Q., Potti A., Chasse D., and Nevins J. R. (2006). Oncogenic pathway signatures in human cancers as a guide to targeted therapies. *Nature*, 43: 353-357.
- Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, and Brandi I (2001). Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. *Br J Pharmacol*, 134: 845–852.
- Bifulco M., Laezza C., Pisanti S. and Gazerro P. (2006). Cannabinoids and cancer: pros and cons of an antitumour strategy. *British Journal of Pharmacology*, 148: 123-135.
- Blasco-Benito S. (2018). Appraising the "Entourage Effect": Antitumor Action of a Pure Cannabinoid Versus a Botanical Drug Preparation in Preclinical Models of Breast Cancer. *Biochem pharmacol*, 157: 285-293.
- Blazquez C, Salazar M, Carracedo A, Lorente M, Egia A, and Gonzalez-Feria L, (2008). Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. *Cancer research*, 68(6): 1945-1952.
- Blazquez C, Carracedo A, Barrado L, Real PJ, Fernandez-Luna JL, and Velasco G., (2006). Cannabinoid receptors as novel targets for the treatment of melanoma. *Faseb j.*, 20(14): 2633-2635.
- Bolas T., and Francis E.E.H. (1869). On the products of the action of nitric acid on the resinous extract of Indian hemp. *J. Chem. Soc.*, 22: 417–419.
- Bogdanović V, Mrdjanović J, and Borišev IA (2017). Review of the therapeutic antitumor potential of cannabinoids. *J Altern Complement Med.*, 23(11):831–836

- Borini P, Guimarães RC, and Borini SB (2004). Possible hepatotoxicity of chronic marijuana usage Sao Paulo Med J., 122(3): 110-16.
- Bossong MG, Mehta MA, van Berckel BN, Howes OD, Kahn RS, and Stokes PR (2015). Further human evidence for striatal dopamine release induced by administration of 9-tetrahydrocannabinol (THC): selectivity to limbic striatum. *Psychopharmacology*, 232: 2723–2729.
- Bottomley D, Ash D, Al-Qaisieh B, Carey B, Joseph J, St Clair S, and Gould K (2007). Side effects of permanent I125 prostate seed implants in 667 patients treated in Leeds. *Radiother Oncol.*, 82(1): 46–49.
- Braun IM, Nayak MM, Revette A, Wright AA, Chai PR, Yusuf M, Pirl WF, and Tulskey JA (2020). Cancer patients' experiences with medicinal cannabis-related care, 127(1): 67–73.
- Brahmi N., Saoudi M., Kadri Y., Kallel C., Euch A.E., Ayadi F.M., Harrath A.H., El Feki A., and Allagui M.S (2019). Protective effect of *Chaetomorpha gracilis* aqueous extract against erythrocytes oxidative damage induced by high fat diet in treated mice. *Arch. Physiol. Biochem.*, 125: 220- 227.
- Bray J., Kretzschmar M., Wunderlich G., Dorr W., Pohl T., Franke WG., and Kotzerke J. (2018). Therapy of malignant ascites in vivo by 211At-labelled microspheres. *Nuklearmedizin*, 43:63– 68.
- Buonaguro L., Petrizzo A., Tornesello M. L. and Buonaguro F. M. (2011) .“Translating tumor antigens into cancer vaccines,”*Clinical & Vaccine Immunology*,18(1): 23– 34.
- Cairns R. A., Harris, I. S., and Mak, T. W. (2011). Regulation of cancer cell metabolism. *Nature Reviews Cancer*, 11(2): 85-95.
- Caffarel M. M., Andradas, C., Pérez-Gómez, E., Guzmán, M. & Sánchez, C. (2012). Cannabinoids: A new hope for breast cancer therapy? *Cancer Treatment Reviews*, 38: 911-918.
- Caja F, Vannucci L. (2015). A player on multiple fronts in the tumor microenvironment. *J Immunotoxicol*, 12 (3): 300–7.
- Calvaruso G., (2012). Cannabinoid-Associated Cell Death Mechanisms in Tumor Models (Review). *Int J. Oncol*, 41(2): 407-13.
- Carmeliet P. and Jain R.K. (2000). Angiogenesis in Cancer and Other Diseases. *Nature*. 407: 249-257.
- Carpi S. (2017). Tumor-Promoting Effects of Cannabinoid Receptor Type 1 in Human Melanoma Cells. *Toxicology in Vitro*, 40: 272-279.

- Casanova M.L., Blázquez, C., Martínez-Palacio, J., Villanueva, C., Fernández-Aceñero, M.J., Huffman, J.W., Jorcano, J.L. and Guzmán, M. (2003). Inhibition of Skin Tumor Growth and Angiogenesis in Vivo by Activation of Cannabinoid Receptors. *The Journal of Clinical Investigation*, 11: 43-50.
- Carvalho M. B. (1997). Historia natural do cancer da cavidade oral . In : Rapoport , A . (Ed.), *Cancer da Boca*. Pancast, Sao Paulo, SP, Brazil, 17 – 29.
- Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimaraes FS (2012). Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. *Philos Trans R Soc Lond Ser B Biol Sci.*, 367: 3364–3378.
- Carracedo A, Lorente M, Egia A, Blazquez C, Garcia S, Giroux V, (2006). The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. *Cancer Cell*, 9(4): 301-312.
- Cesamet (2013). Meda Pharmaceuticals, Sex-dependent effects of cannabis-induced analgesia. *Drug Alcohol Depend*, 167: 112–120.
- Chen X., Bargonetti J., and Prives C. (1995). p53, through p21 (WAF1/ CIP1), induces cyclin D1 synthesis. *Cancer Res.*, 55: 4257–4262.
- Chen L. and Watkins J. F. (1970). Evidence against the presence of H2 histocompatibility antigens in Ehrlich ascites tumour cells, *Nature*, 225(5234):734–735.
- Chen ZM, Xu Z, Collins R, Li WX, Peto R (1997). Early health effects of the emerging tobacco epidemic in China. A 16-year prospective study. *JAMA*, 278: 1500-1504.
- Cragg G. and Newman D. J. (2004). A Tale of Two Tumor Targets: Topoisomerase I and Tubulin. *The Wall and Wani Contribution to Cancer Chemotherapy*, *J. Nat. Prod*, 67, 232-244
- Chakraborty T., Chatterjee A., Saralaya M. G. and Chatterjee M. (2006). Chemopreventive effect of vanadium in a rodent model of chemical hepatocarcinogenesis: reflections in oxidative DNA damage, energy-dispersive X-ray fluorescence profile and metallothionein expression. *J Biol Inorg Chem.*, 11(7): 855-866.
- Chaudhry R., and Varacallo, M. (2019). Biochemistry, Glycolysis. In *Stat Pearls* [Internet]. Stat Pearls Publishing, 11 (2): 89-122.
- Chu R. L., Post D. E., Khuri, F. R., & Van Meir, E. G. (2004). Use of replicating oncolytic adenoviruses in combination therapy for cancer. *Clinical Cancer Research*, 10(16), 299-312.
- Chung K.S. (2019). Beta-Caryophyllene in the Essential Oil from *Chrysanthemum Boreale* Induces G1 Phase Cell Cycle Arrest in Human Lung Cancer Cells, 24(20): 3754.

- Coffey C. and Thompson, B. G. (2009). Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus. United States Paten, 7(6): 082-157.
- Costa-Hurtado, Afonso M., Miller C. L., Shepherd P. J. and Pantin-Jackwood M. J. (2015). Previous infection with virulent strains of Newcastle disease virus reduces highly pathogenic avian influenza virus replication, disease, and mortality in chickens. *Veterinary research*, 46(1): 97.
- Cudaback E. (2010). The Expression Level of Cb1 and Cb2 Receptors Determines Their Efficacy at Inducing Apoptosis in Astrocytomas. *Plos one*, 5(1): 87-102.
- Daris B., Tancer Verboten, Knez Ž. & Ferik P., 2018. Cannabinoids in cancer treatment: Therapeutic potential and legislation, 20 (2): 122-190.
- Das S. K., Sarkar S., Dash R. (2012). Cancer terminator viruses and approaches for enhancing therapeutic outcomes, *Advances in Cancer Research*, 115: 61–38.
- Dasari S, Bernard Tchounwou P. (2014). Cisplatin incancer therapy: molecular mechanisms ofaction. *Eur J Pharmacol*, 740: 364–378.
- Daris B. (2019). Cannabinoids in Cancer Treatment: Therapeutic Potential and Legislation. *Bosn j basic med sci.*, 19(1): 14-23.
- Davis NM, Proctor DM, Holmes SP, Relman DA, Callahan BJ (2018). Simple statistical identification and removal of contaminant sequences in marker-gene and metagenomics data. *Microbiome*, 6(1): 226.
- Deways, W. D. (1982): Pathophysiological of cancer cachexia: Current understanding and areas for future research. *Cancer Res*, 42: 721 –726.
- Delwatta, S.L.; Gunatilake, M.; Baumans, V.; Seneviratne, M.D.; Dissanayaka, M.L.B.; Batagoda, S.S.; Udagedara, A.H.; Walpola, P.B. (2018). Reference values for selected hematological, biochemical and physiological parameters of Sprague-Dawley rats at the Animal House, Faculty of Medicine, University of Colombo, Sri Lanka. *Animal Models and Experimental Medicine*, 1, 250-254.
- De Weger V. A., Turksma A. W., Voorham Q. J. M. (2012). “Clinical effects of adjuvant active specific immunotherapy differ between patients with microsatellite-stable and microsatellite-unstable colon cancer,” *Clinical Cancer Research*, 18(3): 882–889.
- Deepak Narang, (2022). *Einstein International Journal Organization EIJO.*, 7 (3), 22 – 30.
- Devane, W.A., Dysarz, F.A., III, Johnson, M.R., Melvin, L.S., and Howlett, A.C. (1988). Determination and characterization of a cannabinoid receptor in rat brain. *Mol. Pharmacol*, 34: 605–613.

- De Petrocellis L, Ligresti A, Schiano Moriello A, Iappelli M, Verde R, Stott CG, Cristino L, Orlando P, Di Marzo V (2013) Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms. *Br J Pharmacol*, 168(1):79–102.
- Deyrup A.T., V.K. Lee, C.E. Hill, W. Cheuk, H.C. Toh, S. Kesavan, E.W. Chan, and S.W. Weiss, (2006). Epstein-Barr virus-associated smooth muscle tumors are distinctive mesenchymal tumors reflecting multiple infection events: a clinicopathologic and molecular analysis of 29 tumors from 19 patients. *Am J Surg Pathol.*, 30(1): 75- 82.
- Dhup S., Kumar Dadhich, R., Ettore Porporato, P., & Sonveaux, P. (2012). Multiple biological activities of lactic acid in cancer: influences on tumor growth, angiogenesis and metastasis. *Current pharmaceutical design*, 18(10), 1319-1330.
- Ding H., Han, C., Guo, D., Chin, Y. W., Ding, Y., Kinghorn, A. D., & D'Ambrosio, S. M. (2009). Selective induction of apoptosis of human oral cancer cell lines by avocado extracts via a ROS-mediated mechanism. *Nutrition and cancer*, 61(3), 348-356.
- Di Marzo V (2018) New approaches and challenges to targeting the endocannabinoid system. *Nat Rev Drug Discovry*, 17:623–639.
- Donadelli, M. (2011). Gemcitabine/Cannabinoid Combination Triggers Autophagy in Pancreatic Cancer Cells through a Ros-Mediated Mechanism. *Cell Death Dis.*, 2: 152.
- Dongre A, Weinberg RA (2019). New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. *Nat Rev Mol Cell Bio.*, 20: 69–84.
- Dolai N, Karmakar I, Suresh Kumar RB, Kar B, BalaA, Haldar PK. (2012). Evaluation of antitumor activity and in vivo antioxidant status of *Anthocephalus cadamba* on Ehrlich ascites carcinoma treated mice. *J Ethnopharmacol*, 142:865-70.
- Dongre SH, Badami S, Natesan S, Chandrashekhar RH (2007). Antitumor activity of the methanol extract of *Hypericum hookerianum* stem against ehrlich ascites carcinoma in swiss albino mice. *J Pharmacol Sci.*, 103:354–359.
- Drake C. G., Lipson E. J., and Brahmer J. R. (2014). “Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer,” *Nature Reviews Clinical Oncology*, 11(1): 24–37.
- Dranoff G., Jaffee E., Lazenby A. (1993) “Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity,” *Proceedings of*

- the National Academy of Sciences of the United States of America, 90 (8): 3539–3543.
- D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G (2005). Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. *Biol Psychiatry*, 57: 594–608.
- D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. *Neuropsychopharmacology*, 29: 1558–1572.
- Eertwegh J. Versluis H. P., and Berg (2012). “Combined immunotherapy with granulocyte- macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with meta- static castration-resistant prostate cancer: a phase 1 dose- escalation trial,” *Lancet Oncology*, 13(5): 509– 517.
- Eisenberg-Lerner A, Bialik S, Simon HU, Kimchi A (2009). Life and death partners: apoptosis, autophagy and the cross-talk between them. *Cell Death Differ.*, 16(7): 966- 975.
- ElSohly MA, Radwan MM, Gul W, Chandra S, Galal A. (2017). *Phytochemistry of Cannabis sativa LPhytocannabinoids*. A. Douglas Kinghorn, Heinz Falk, Simon Gibbons, Jun'ichi Kobayashi (eds). Springer: Switzerland, 1–36.
- Emens L. A., Asquith J. M., Leatherman J. M. (2009). “Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemo-therapy dose-ranging factorial study of safety and immuneactivation,” *Journal of Clinical Oncology*, 27(35): 5911–5918.
- Eriksson M., L. Hardell, and H.O. Adami (1990). Exposure to dioxins as a risk factor for soft tissue sarcoma: a population-based case-control study. *J Natl Cancer Inst.*, 82(6): 486-90.
- Espuelas S., A. Roth, C. Thumann, B. Frisch, and F. Schuber (2005). “Effect of synthetic lipopeptides formulated in liposomes on the maturation of human dendritic cells,” *Molecular Immunology*, 42(6): 721–729.
- Elson DA, Riley RR, Lacey A, Thordarson G, Talamantes FJ, Arbeit JM (2000). Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis. *Cancer Res.*, 60(5):1267-75.

- Farkas I, Kallo I, Deli L, Vida B, Hrabovszky E, Fekete C (2010). Retrograde endocannabinoid signaling reduces GABAergic synaptic transmission to gonadotropin-releasing hormone neurons. *Endocrinology*, 151: 5818–5829.
- Ferraro B., M. P. Morrow, N. A. Hutnick, T. H. Shin, C. E. Lucke, and D. B. Weiner (2011). “Clinical applications of DNA vaccines: current progress,” *Clinical Infectious Diseases*, 53(3): 296–302.
- Fecchio D., Sirois P., Russo M. and Jancar S. (1990). “Studies on inflammatory response induced by Ehrlich tumor in mice peritoneal cavity”, *Inflammation*, 14(1):125-132.
- Fishman M., Hunter T. B. and Soliman H. (2010). “Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma,” *Journal of Immunotherapy*, 31(1): 72–80.
- Flores-Sanchez, I.J., and Verpoorte, R. (2008). Secondary metabolism in cannabis. *Phytochem. Rev.*, 7, 615–639.
- Fogaca MV, Reis FM, Campos AC, and Guimaraes FS (2014). Effects of intra-prelimbic prefrontal cortex injection of cannabidiol on anxiety-like behavior: involvement of 5HT1A receptors and previous stressful experience. *Eur Neuropsychopharmacol*, 24: 410–419.
- Fournier P., and Schirmacher, V. (2013). Oncolytic Newcastle disease virus as cutting edge between tumor and host. *Biology*, 2(3), 936-975.
- Friend S.H., R. Bernards, S. Rogelj, R.A. Weinberg, J.M. Rapaport, D.M. Albert, and T.P. Dryja (1986). A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. *Nature*, 323(6089): p. 643-6.
- Fu Y., Li J., and Lee A. S. (2007). GRP78/BiP inhibits endoplasmic reticulum BIK and protects human breast cancer cells against estrogen starvation-induced apoptosis. *Cancer research*, 67(8), 3734-3740.
- Gaze D.C., 2007. The role of existing and novel cardiac biomarkers for cardioprotection. *Curr. Opin. Invest. Drugs* 8 (9), 711–717.
- Galve-Roperh I, Sa´nchez C, Corté´s ML, del Pulgar TG, Izquierdo M, Guzmán M. (2000). Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. *Nat Med.*, 6: 313-9.
- Galluzzi L, Pietrocola F, Bravo-San Pedro JM, Amaravadi RK, Baehrecke EH, Cecconi F, (2015). Autophagy in malignant transformation and cancer progression. *Embo J. Oncogene*; 21: 122–291.

- Gaoni Y, Mechoulam R (1964). Isolation, structure, and partial synthesis of an active constituent of hashish. *J Am Chem Soc.*, 86: 1646–1647.
- Ghosh T, Maity TK, Singh J. (2011). Evaluation of antitumor activity of stigmasterol, a constituent isolated from *Bacopa monnieri* Linn aerial parts against Ehrlich Ascites Carcinoma in mice. *Orient Pharm Exp Med.*, 11:41-9.
- Gill, K. S., Fernandes, P., O'Donovan, T. R., McKenna, S. L., Doddakula, K. K., Power, D. G. & Forde, P. F. (2016). Glycolysis inhibition as a cancer treatment and its role in an anti-tumour immune response. *Biochimica et Biophysica Acta (BBA)-Reviews on Cancer*, 1866(1), 87-105.
- Goodrick CL. (1980). Effects of long-term voluntary wheel exercise on male and female Wistar rats. I. Longevity, body weight, and metabolic rate. *Gerontology*, 26:22-33.
- Gomes FV, Reis DG, Alves FH, Correa FM, Guimaraes FS, Resstel LB (2012). Cannabidiol injected into the bed nucleus of the stria terminalis reduces the expression of contextual fear conditioning via 5-HT1A receptors. *J Psychopharmacol*, 26: 104–113.
- Goncalves, J. (2019). Cannabis and Its Secondary Metabolites: Their Use as Therapeutic Drugs, Toxicological Aspects, and Analytical Determination, 6(1):31.
- Gonin-Giraud, S., Mathieu, A. L., Diocou, S., Tomkowiak, M., Delorme, G., & Marvel, J. (2002). Decreased glycolytic metabolism contributes to but is not the inducer of apoptosis following IL-3-starvation. *Cell death and differentiation*, 9(10), 1147.
- Goos P. and Jones B. (2011). *Design of Experiments: A Case-Study Approach*. New York, NY: Wiley. 11 (1): 13-23.
- Grier H.E., M.D. Krailo, N.J. Tarbell, M.P. Link, C.J. Fryer, D.J. Pritchard, M.C. Gebhardt, P.S. Dickman, E.J. Perlman, P.A. Meyers, S.S. Donaldson, S. Moore, A.R. Rausen, Gupta M, Mazumder UK, Sambath Kumar R, Sivakumar T, Mohan vamsi ML (2004). Antitumor Activity and Antioxidant Status of *Caesalpinia bonducella* Against Ehrlich Ascites Carcinoma in Swiss Albino Mice. *J. Pharmacol. Sci.* 94: 177-184.
- Grimaldi C, Pisanti S, Laezza C, Malfitano AM, Santoro A, Vitale M, (2006). Anandamide inhibits adhesion and migration of breast cancer cells. *Exp Cell Res* 312(4): 363-373.
- Guo Z. S. (2018). The 2018 Nobel prize in medicine goes to cancer immunotherapy (editorial for BMC cancer).

- Gustafsson, S.B. (2009). Cannabinoid Receptor-Independent Cytotoxic Effects of Cannabinoids in Human Colorectal Carcinoma Cells: Synergism with 5-Fluorouracil. *Cancer Chemother Pharmacol*, 63(4): p. 691-701.
- GuoW., Lu X., Liu Q, Zhang T., Li P., Qiao W., (2016). *Cancer*; 148: 2906–2914.
- Guzmán J, Esmail R, Karjalainen K, Malmivaara A, Irvin E, Bombardier C, (2001). Multidisciplinary rehabilitation for chronic low back pain: systematic review. *BMJ*. 322:1511–1516.
- Guo W., Lu X., Liu Q, Zhang T., Li P., Qiao W., of *Cancer*; 148: 2906–2914.
- Gulley J. L., Arlen P. M., Madan R. A. (2010). “Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer,” *Cancer Immunology, Immunotherapy*, 59(5):663–674.
- Hailemichael Y., Dai Z., Jaffarzad N. (2013). “Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion,” *Nature Medicine*, 19(4): 465–472.
- Hanahan D, Weinberg RA. (2000). Hallmarks of cancer: the next generation. *Cell*. 144 (5): 646–74.
- Hampson RE, Miller F, Palchik G, Deadwyler SA (2011). Cannabinoid receptor activation modifies NMDA receptor mediated release of intracellular calcium: implications for endocannabinoid control of hippocampal neural plasticity. *Neuropharmacology* 60: 944–952.
- Harada M., Udagawa N., Fukasawa K., Hiraoka B.Y., Mogi M. (1986). Inorganic pyrophosphatase activity of purified bovine pulp alkaline phosphatase at physiological pH. *J. Dent. Res.* 65 (2), 125– 127.
- Harris J. E., Ryan L., Hoover H. C. (2000). Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283,” *Journal of Clinical Oncology*, 18, (1):148–157.
- Haldar PK, Kar B, Bala A, Bhattacharya S, Mazumder UK. (2010). Antitumor activity of *Sansevieria roxburghiana* rhizome against Ehrlich ascites carcinoma in mice. *Pharm Biol*;48:1337-43.
- Haldar P. K.; Bhattacharya S.; Kar B.; Bala A.; Mazumder U. K., (2010): Chemopreventive role of *Indigofera aspalathoides* in 20- methylcholanthrene induced carcinogenesis in mouse. *Toxicological and Environmental Chemistry*, 92:1749–1763.

- Haldar PK, Kar B, Bala A, Bhattacharya S, Mazumder UK. (2010). Antitumor activity of *Sansevieria roxburghiana* rhizome against Ehrlich ascites carcinoma in mice. *Pharm Biol*;48:1337-43.
- Hart S., Fischer O.M., and Ullrich A. (2004). Cannabinoids Induce Cancer Cell Proliferation Via Tumor Necrosis Factor A-Converting Enzyme (Tace/Adam17)-Mediated Transactivation of the Epidermal Growth Factor Receptor. *Cancer Research*. 64: p. 1943–1950.
- Hanna M. G., Hoover H. C., Vermorken J. B., Harris J. E. and H. M. Pinedo (2001). Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise *Vaccine*, 19(17–19): 2576–2582.
- Hasko J. (2014). Cb2 Receptor Activation Inhibits Melanoma Cell Transmigration through the Blood-Brain Barrier. *International journal of molecular science*, 15(5): p. 8063-8074.
- Herbein G, Kumar A. (2014). The oncogenic potential of human cytomegalovirus and breast cancer. *Front Oncol*. 4: 230.
- Hos B. J., Tondini E., van Kasteren S. I., and Ossendorp F. (2018). “Approaches to improve chemically defined synthetic peptide vaccines,” *Frontiers in Immunology*, 9: 884–891.
- Hodge J. W., Chakraborty M., Kudo-Saito C., Garnett C. T., and J. Schlom (2005) “Multiple costimulatory modalities enhance CTL avidity,” *Journal of Immunology*, 174(10): 5994–6004.
- Holland M.L., J.D. Allen, and J.C. Arnold (2008). Interaction of Plant Cannabinoids with the Multidrug Transporter Abcc1 (Mrp1). *Eur pharmacol*. 591(1-3): 128-31.
- Huang M. (2012). Terpenoids: Natural Products for Cancer Therapy. *Expert opin investing drugs*. 21(12): 1801-18.
- Hussain SP, Harris CC. (2007). Inflammation and cancer: an ancient link with novel potentials. *Int J Cancer*.;121(11):2373–80.
- Huvos A., (1991). Bone tumours: diagnosis, treatment, and prognosis. 2nd ed., Philadelphia: W.B.Saunders Company. *Int J Cancer*.;202(121):17–53.
- Hyman SM, Sinha R (2009). Stress-related factors in cannabis use and misuse: implications for prevention and treatment. *J Subst Abuse Treat.*, 36: 400–413.
- Hyogo uo (2006). Science GS of NA and. Disaster Nursing in a Ubiquitous Society Care Package for Cancer Patients In Times of Handbook of Self-Managing. Side

- Effects of Chemotherapy in Times of Disaster. In: Handbook of Self-Managing Side Effects of Chemotherapy in Times of Disaster; 22(3): 1–26.
- Ihedioha JI, Noel-Uneke OA, Ihedioha TE., (2013). Reference values for the serum lipid profile of albino rats (*Rattus norvegicus*) of varied ages and sexes. *Comp Clin Pathol.*; 22:93-119.
- Islam A, Eden T. Brief report on pediatric oncology in Bangladesh. *South Asian J Cancer* 2013;2:105-6.
- Issa J.S., Santos P.C., Vieira L.P., Abe T.O., Kuperszmidt C.S., Nakasato M. (2014). Smoking cessation and weight gain in patients with cardiovascular disease or risk factor. *International Journal Cardiology*; 172(2):485–487
- Izzo A.A., Borrelli F., Capasso R., Di Marzo V., Mechoulam R. (2009). Non-psychoactive plant cannabinoids: new therapeutic opportunities from an ancient herb. *Trends Pharmacol Sci.*, 30: 515–527.
- Izzo A., Borrelli F., Capasso R., Di Marzo V. and Mechoulam R. (2009). Non-psychoactive plant cannabinoids: new therapeutic opportunities from an ancient herb. *Trends in Pharmacological Sciences*, 30, 515-527.
- Izhevskiy EV (2004). Practical work on experimental oncology on example of Ehrlich ascitic carcinoma: methodic elaboration. *Nauka, Krasnoyarsk.*, 12(1): 163-173.
- Jackson SJ, Andrews N, Ball D, Bellantuono I, Gray J and Hachoumi L. (2017). Does age matter? The impact of rodent age on study outcomes. *Lab Anim.*, 51:160-219.
- Jacob A. and Todd A.R.C. (1940). *Cannabis indica*. part II. Isolation of cannabidiol from Egyptian hashish observations on the structure of cannabinol. *J. Chem. Soc.*, 10: 649–653.
- Jaishree V., Badami S., and Suresh B., (2008). In vitro antioxidant activity of *Enicostemma axillare*, *J. Health Sci.*, in press. 21(4): 63-73.
- Janssen E. M., Droin N. M., Lemmens E. E. (2005). “CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death,” *Nature*, 434 (7029): 88–93.
- Javid F. A., Phillips R. M., Afshinjavid S., Verde R. and Ligresti A. (2016). Cannabinoid pharmacology in cancer research: A new hope for cancer patients? *European Journal of Pharmacology*, 775, 1-14.
- Jaffee E. M., Hruban R. H., Biedrzycki B. (2001). “Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation,” *Journal of Clinical Oncology*, 19(1):145–156.

- Jemal A, Bray F, Melissa M, Ferlay J, Ward E, Forman D. (2011). Global Cancer Statistics. *CA Cancer J Clin.* 61: 69–90.
- Jemal A., Siegel R., Xu J. and Ward E. (2010): Cancer Statistics *CA Cancer. J Clin*, 60: 227 – 300.
- Jenner, R.G. and C. Boshoff (2002). The molecular pathology of Kaposi's sarcoma-associated herpesvirus. *Biochim Biophys Acta*, 1602(1): 1-22.
- Jin L.Z., Rangan, A., Mehlsen, J., Andersen, L.B., Larsen, S.C., Heitman, B.L.(2017). Association Between Use of Cannabis in Adolescence and weight Change into midlife. *PLoS ONE*; 12(1): 163-173.
- Jin J. H., Cheng J. L., He Z. R., and Ren, Y. C., (2017). Different Origins of Newcastle Disease Virus Hemagglutinin Neuraminidase Protein Modulate the Replication Efficiency and Pathogenicity of the Virus. *Frontiers in microbiology*, 8, 1607.
- Johnston, M. I. and Fauci, A. S. (2007). An HIV vaccine evolving concepts. *N. Engl. J. Med*, 356: 2073 – 81.
- Jones, R.L., C. Fisher, O. Al-Muderis, and I.R. Judson (2005). Differential sensitivity of liposarcoma subtypes to chemotherapy. *Eur J Cancer*, 41(18): 253-260.
- Jorritsma S. H. T., Gowans E. J., Grubor-Bauk B., and Wijesundara D. K. (2016). “Delivery methods to increase cellular uptake and immunogenicity of DNA vaccines,” *Vaccine*, vol. 34, no. 46: 5488–5494.
- Julie Thompson, Kathryn Siliman, Dawn E Clifford (2013). Impact of an early education multimedia intervention in managing nutrition-related chemotherapy side effects. *springerPlus*. 2:179.
- Karmen A, Wroblewski F, Ladue JS, (2008). Transaminase activity in Human blood. *J Clin Invest.*, 34:126-33.
- Kanematsu Sugiura (1953). Effect of Various Compounds on the Ehrlich Ascites Carcinoma *Cancer Res.*, 13:431-441.
- Kaplan BW. (2013). Priority medicines for Europe and the world “ A public health approach to innovation “ update on 2004 background paper written by Warren Kaplan background paper 6. *Cancer Ther.*, 3(2):5–62.
- Kathriya A., Das K., Kumar EP., Mathai KB. (2010). Evaluation of antitumor activity of *Oxalis corniculata* Linn. Against Ehrlich ascites carcinoma on mice. *Iran J Cancer Prev.*, 4:157-65.
- Kelly P., Jones, R.T. (1992). Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. *Journal of analytical toxicology*, 16(4): 228-235.

- Kim SR and Kim DY (2020). cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. *Sci Rep.*, 10:20622.
- Kilkenny C, Parsons N, Kadyszewski E, Festing MF, Cuthill IC, Fry D (2009). Survey of the quality of experimental design, statistical analysis and reporting of research using animals. *PloS One.*, 4: 7824.
- Koppenol, W. H., Bounds, P. L., & Dang, C. V. (2011). Otto Warburg's contributions to current concepts of cancer metabolism. *Nature Reviews Cancer*, 11(5): 325.
- Kovalchuk O, Kovalchuk I. (2020). Cannabinoids as anticancer therapeutic agents. *Cell Cycle*. 19: 961–89.
- Kim JH, Evans TS (1964). Effects of X-irradiation on the mitotic cycle of Ehrlich ascites tumor cells. *Rad Res* 21:129–143.
- Kinoshita Y., Kono T., Yasumoto R. (2001). “Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony- stimulating factor and interleukin-6 cells,” *Journal of Immunotherapy*, 24(3): 205–211.
- Kranz L. M., Diken M., Haas H. (2016). “Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy,” *Nature*, 534 (7607):396–401.
- Ladin DA, Soliman E, Grifn L, Van Dross R (2016). Preclinical and clinical assessment of cannabinoids as anti-cancer agents. *Front Pharmacol* 7:361
- Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM (2015). Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. *Br J Pharmacol* 172: 4790–4805.
- Lettre R, Paweletz N, Werner D, Granzow C (1972). Sublines of the Ehrlich-Lettre Mouse Ascites Tumor, A New Tool for Experimental Cell Research. *Naturwissenschaften*, 59: 59-63.
- Leiserson MD, Blokh D, Sharan R, Raphael BJ. (2013). Simultaneous identification of multiple driver pathways in cancer. *PLoS Comput Biol.* 9 (5): e1003054.
- Li Q, Yan H, Wilson WA, Swartzwelder HS (2010). Modulation of NMDA and AMPA-mediated synaptic transmission by CB1 receptors in frontal cortical pyramidal cells. *Brain Res* 1342: 127–137.
- Ligresti, A. (2006). Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma. 318(3): p. 1375-87.

- Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L (2006). Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. *J Pharmacol Exp Ther* 318: 1375–1387.
- Liu W.M. (2008). Enhancing the in Vitro Cytotoxic Activity of Delta9 Tetrahydrocannabinol in Leukemic Cells through a Combinatorial Approach. *49(9):1800-1809*
- Liu T., Hwang H., Bell J. C., and Kirn D. H. (2008). “Translation of targeted oncolytic virotherapeutics from the lab into the clinic, and back again: a high-value iterative loop,” *Molecular Therapy*, 16(6):1006–1008.
- Lindsey A. Torre, Freddie Bray, Rebecca L. Siegel, Jacques Ferlay, Joannie Lortet-Tieulent, Ahmedin Jemal, (2015), *Cancer J Clin*; 65:87–108.
- Liu L., Chen Q., Ruan C. (2018). “Platinum-based nanovectors engineered with Immunomodulating adjuvant for inhibiting tumor growth and promoting immunity,” *Theranostics*, 8(11):2974–2987.
- Li D., Romain G., Flamar A. (2012). “Targeting self- and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4⁺ T cells,” *Journal of Experimental Medicine*, 209(1): 109–121.
- Lohman AC, Van Rijn I, Lindhardt CL, Vonthein R, Rades D and Holländer NH. (2018). Preliminary results from a prospective study comparing white blood cell and neutrophil counts from a laboratory to those measured with a new device in patients with breast cancer. *In Vivo*;32(5):1283–1288.
- Loeb, L. A., Loeb, K. R., and Anderson, J. P. (2003). Multiple mutations and cancer. *Proceedings of the National Academy of Science*, 100(3), 776-781.
- Lukhele ST and Motadi LR (2016). Cannabidiol rather than Cannabis sativa extracts inhibit cell growth and induce apoptosis in cervical cancer cells. *BMC Complement Altern Med* 16(335):1–16
- Luksiene Z, Juzenas P and Moan J (2006). Radiosensitization of tumours by porphyrins. *Cancer Lett* 235:40–47.
- Lin HS and D’Rosario T (2003). Pretreatment growth environment alter the sensitivity of tumor cells to cytotoxic agents. *Free Radical Biol Med* 35:277–283.
- Lu Y., Zhang X., Zhang H., Lan J., Huang G., Varin E., and Icard P. (2011). Citrate induces apoptotic cell death: a promising way to treat gastric carcinoma? *Anticancer research*, 31(3): 797-805.
- Luksiene Z, Juzenas P, Moan J (2006). Radiosensitization of tumours by porphyrins. *Cancer Lett*, 235: 40–47.

- Madhuri S., Pandey G. (2009). Some anticancer medicinal plants of foreign origin. *Current Science*, 96 (6) 779-783.
- Majewski, M.; Ognik, K.; Ju'skiewicz, J. (2020). The antioxidant status, lipid profile, and modulation of vascular function by fish oil supplementation in nano-copper and copper carbonate fed Wistar rats. *J. Funct. Foods*, 64, 103595.
- Mansour, S. Z. and Anis, L. M. (2010). possible effect of 5, 6 – dimethyle – 4 isothiocyanate thieno [2,3 – d] pyrimidine and / or irradiation on Ehrlich carcinoma in mice . *J. Rad. Res. Appl. Sci*, 3 (2B): 599 - 618.
- Marincola F. M., Jaffee E. M., Hicklin D. J., and Ferrone S. (1999). “Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance,”*Advances in Immunology*,74:181–273.
- Massi P, Valenti M, Vaccani A, Gasperi V, Perletti G, Marras E, (2008). 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. *J Neurochem* 104(4): 1091-1100.
- Mach N., Gillessen S., Wilson S. B., Sheehan C., Mihm M., and Dranoff G. (2000). “Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte- macrophage colony-stimulating factor or Flt3-ligand,” *Can-cer Research*, 60(12): 3239–3246.
- Maver C. and McKneally M. (1979). “Preparation of autologous tumor cell vaccine from human lung cancer,” *Cancer Research*, 39(8): 23-89.
- Manojkumar P, Ravi T, Subbuchettiar G. (2009). Synthesis of coumarin heterocyclic derivatives with antioxidant activity and in vitro cytotoxic activity against tumour cells. *Acta Pharm*;59:159-60.
- Magen I, Avraham Y, Ackerman Z, Vorobiev L, Mechoulam R, Berry EM (2010). Cannabidiol ameliorates cognitive and motor impairments in bile-duct ligated mice via 5-HT1A receptor activation. *Br J Pharmacol* 159: 950–957.
- Malkin D., F.P. Li, L.C. Strong, J.F. Fraumeni, Jr., C.E. Nelson, D.H. Kim, J. Kassel, M.A. Gryka, F.Z. Bischoff, M.A. Tainsky (1990). Germ line p53 mutations in a 38 familial syndrome of breast cancer, sarcomas, and other neoplasms. *Science*,. 250(4985): 1233-8.
- Marcu J.P. (2010). Cannabidiol Enhances the Inhibitory Effects of Delta9 Tetrahydrocannabinol on Human Glioblastoma Cell Proliferation and Survival. *Mol cancer ther.* 9(1): 180-9.
- Mckallip R.J., Nagarkatti M. and Nagarkatti, P.S. (2005). Delta-9-Tetrahydrocannabinol Enhances Breast Cancer Growth and Metastasis by Suppression of the Antitumor Immune Response. *The Journal of Immunology*, 174, 3281-3289.

- Mckaign RG, Baric RS, Olshan AF (1998). Human papillomavirus and head and neck cancer: epidemiology and molecular biology. *Head Neck*. 20(3):250-65.
- Mcallister SD, Soroceanu L, Desprez PY, (2015). The antitumor activity of plant derived non-psychoactive cannabinoids. *J Neuroimmune Pharmacol*;10(2):255-67
- Mcmahon LR (2016). Enhanced discriminative stimulus effects of Delta(9)-THC in the presence of cannabidiol and 8-OH-DPAT in rhesus monkeys. *Drug Alcohol Depend* 165: 87–93.
- Melief C. J. M. and Van der Burg S. H. (2008). “Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines,” *Nature Reviews Cancer*, vol. 8, no. 5, pp. 351– 360.
- Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO (2007). Cannabidiol—recent advances. *Chem Biodivers* 4: 1678–1692. Mechoulam R, Shani A, Edery H, Grunfeld Y (1970). Chemical basis of hashish activity. *Science* 169: 611–612.
- Meier MH, Caspi A, Ambler A, Harrington HL, Houts R, Keefe RSE (2012). Persistent cannabis users show neuropsychological decline from childhood to midlife. *Proc Natl Acad Sci* 109: E2657–E2664.
- Melck D., De Petrocellis, L., Orlando, P., Bisogno, T., Laezza, C., Bifulco, M. and Di Marzo, V. (2000) Suppression of Nerve Growth Factor Trk Receptors and Prolactin Receptors by Endocannabinoids Leads to Inhibition of Human Breast and Prostate Cancer Cell Proliferation. *Endocrinology*, 141, 118-126.
- Mizushima N, Levine B, Cuervo AM, Klionsky DJ (2008). Autophagy fights disease through cellular self-digestion. *Nature* 451(7182): 1069-1075.
- Miyagi T, Takahashi K, Shiozaki K, Yamaguchi K, Hosono M. (2015). Plasma membrane-associated sialidase confers cancer initiation, promotion and progression. *Adv Exp Med Biol*. 842: 139–45.
- Mouabbi J., Zein, R., Susanna, S., Saravolatz, L., Kafri, Z., Hadid, T. (2017). Neutrophil-to Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Predictive markers for DVT. *Chest Annual Meeting*;152(4):A1041.
- Moy E, Garcia MC, Bastian B. (2017). Leading causes of death in nonmetropolitan and metropolitan areas — United States, 1999–2014. *MMWR Surveill Summ*. 66(No. SS-1):1–8.
- Morton D. L., Foshag L. J., Hoon D. S. B. (1992). “Prolongation of Survival in Metastatic Melanoma after Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine,” *Annals of Surgery*, 216(4):463–482.

- Munson A.E. (1975). Antineoplastic Activity of Cannabinoids. *Journal of The National Cancer Institute*. 55: 597-602.
- Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA. (1975). Antineoplastic activity of cannabinoids. *J Natl Cancer Inst.*, 55:597-602.
- Mycek E.M., Werner D., Greeff E.A., and Taylor D.A., (1998). Postradiation sarcomas: 20 cases and a literature review. *Int J Radiat Oncol Biol Phys.*, 45(4): 951-61.
- Marsit C. J., Karagas, M. R., Danaee, H., Liu, M., Andrew, A., Schned, A., . . . Kelsey, K. T. (2006). Carcinogen exposure and gene promoter hypermethylation in bladder cancer. *Carcinogenesis*, 27(1): 112-116.
- Mechoulam, R. and S. Ben-Shabat (1999). From Gan-Zi-Gun-Nu to Anandamide and 2-Arachidonoylglycerol: The Ongoing Story of Cannabis, (16):131-143.
- Miller K. D., Nogueira L., Mariotto A. B., Rowland J. H., Yabroff K. R., Alfano C. M., and Siegel, R. L. (2019). Cancer treatment and survivorship statistics, 2019. *CA: a cancer journal for clinicians*, 69(5): 363-385.
- Murase R, Kawamura R, Singer E, Pakdel A, Sarma P, Judkins J, (2014). Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer. *British journal of pharmacology*, 171(19): 4464-4477.
- Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA, (1975). Antineoplastic activity of cannabinoids. *J Natl Cancer Inst.*, 55:597–602.
- Nabissi M, Morelli MB, Santoni M, Santoni G (2012). Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. *Carcinogenesis*, 34(1): 48-57.
- Nascimento FRT, Cruz GVB, Pereira PVS, Maciel MCG, Silva LA, Azevedo APS, Barroqueiro ESB, Guerra RNM (2006). Ascitic and solid Ehrlich tumor inhibition by *Chenopodium ambrosioides* L. treatment. *Life Sci.*, 78:2650–265.
- Nemunaitis J. and Nemunaitis J. (2003). “Granulocyte-macrophage colony-stimulating factor gene-transfected autologous tumor cell vaccine: focus on non-small-cell lung cancer,” *Clinical Lung Cancer*, 5(3):148–157.
- Nemunaitis J., Jahan T., Ross H. (2006). “Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX® vaccine in advanced-stage non-small-cell lung cancer,” *Cancer Gene Therapy*, 13(6):555–562.
- Nestle F. O., Alijagic S., Gilliet M. (1998). “Vaccination of mel-anoma patients with peptide- or tumorlysate-pulsed den-dritic cells,” *Nature Medicine*, 4(3):328–332.

- Noronha V, Tsomo U, Jamshed A, Hai MA, Wategama S, Baral RP (2012). A fresh look at oncology facts on south central Asia and SAARC countries. *South Asian J Cancer*;1:1-4.
- Nuutinen T. (2018). Medicinal Properties of Terpenes Found in Cannabis Sativa and Humulus Lupulus. *EUR J MED CHEM*,. 157: 198-228.
- Obayed R, Syed MT and Afrina B, (2012). Evaluation of antitumor activity of *Leea indica* (Burm.f.) Merr. Extract against Ehrlich Ascites Carcinoma (EAC) bearing mice. *Am. J. Biomed. Sci* 4, 143-152
- Ockert D., Schirmacher V., Beck N. (1996). "Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma," *Clinical Cancer Research*, 2 (1): 21– 28.
- Oshiumi H., Matsumoto M., Funami K., Akazawa T., and T. Seya (2003). "TICAM-1, an adaptor molecule that participates in toll-like receptor 3-mediated interferon-beta induction," *Nature Immunology*., 4(2):161–167.
- Okay HG (1998). Deneysel EAT Oluşturulan Fare Karaciğer Plazmasında Nitrik Oksit Metabolizmasının İncelenmesi. 32(3): 263-273.
- Ozaslan M, Karagöz ID, Kilic IH, Cengiz B, Kalender ME, Guldur ME, Karagöz A, Zümrütdal ME (2009). Effect of *Plantago major* sap on Ehrlich ascites tumours in mice. *Afr. J. Biotechnol.* 8(6): 955-959.
- Ozaslan M, Zümrütdal ME, Dağlıoğlu K, Kilic IB, Karagöz ID, Kalender ME, Tuzcu M, Colak O and Cengiz B (2009). Antitumoral Effect of *L. inermis* in Mice with EAC. *Int. J. Pharmacol.* 5(4): 263-267.
- Ozaslan M, Didem Karagöz I, Kalender ME, Kilic IH, Sari I, Karagöz A (2007). In vivo antitumoral effect of *Plantago major* L. extract on Balb/C mouse with Ehrlich ascites tumor. *Am. J. Chin. Med.* 35(5): 841-851.
- Ozaslan M, Karagoz ID, Kilic IH, Guldur ME. (2011). Ehrlich ascites carcinoma. *Afr J Biotechnol*;10:2375-8.
- Pascolo S. (2008). "Vaccination with messenger RNA (mRNA)," *Handbook of Experimental Pharmacology*, 183(3): 221–235.
- Pagano J. S., Blaser M. and Buendia, M. A. (2004). Infectious agents and cancer : criteria for a casual relation. *Semin. Cancer Biol*, 14(6): 453- 71.
- Park B, Lee HS, Lee JW and Park S. (2019). Association of white blood cell count with breast cancer burden varies according to menopausal status, body mass index, and hormone receptor status: a case-control study. *Sci Rep.*;9(1):5762.

- Patt H. M. and Straube R. L. (1956). Measurement and nature of ascites tumor growth, *Annals of the New York Academy of Sciences.*, 63(5):728–737.
- Paul R., Kulkarni P., and Ganesh N. (2011). Avocado fruit (*Persea americana* Mill) exhibits chemo-protective potentiality against cyclophosphamide induced genotoxicity in human lymphocyte culture. *J Exp Ther Oncol*, 9(3), 221-30.
- Prabhakar BT, Khanum SA, Jayashree K, Salimath BP, Shashikanth S (2006). Anti-tumor and proapoptotic effect of novel synthetic benzophenone analogues in Ehrlich ascites tumor cells. *Bioorg. Med Chem* 14:435–446.
- Portenoy RK, Ganae-Motan ED, Allende S, Yanagihara R, Shaiova L, Weinstein S (2012). Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. *J Pain* 13: 438–449.
- Punglia RS, Burstein HJ, Weeks JC. (2012). Radiation therapy for ductal carcinoma in situ: a decision analysis. *Cancer*. 118: 603–611.
- Porter AC, Felder CC. (2001). The endocannabinoid nervous system: Unique opportunities for therapeutic intervention. *Pharmacol Ther*, 90:45-60.
- Pertwee R.G. (1997). Pharmacology of Cannabinoid CB1 and CB2 Receptors. *Pharmacology & Therapeutics*, 74, 129-180.
- Pertwee RG (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. *Br J Pharmacol* 153: 199–215.
- Petit F, Jeantaud B, Reibaud M, Imperato A, Dubroeuq MC (1998). Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. *Life Sci.*, 63: 1–6.
- Press DJ, Pierce B, Lauderdale DS (2020) Tobacco and marijuana use and their association with serum prostate-specific antigen levels among African American men in Chicago. *Prev Med Rep* 20:174
- Petrovic N. (2016). Targeting Angiogenesis in Cancer Treatments: Where Do We Stand? *J Pharma Sci*. 19: 226-238
- Picardi P. (2014). Anandamide Inhibits Breast Tumor-Induced Angiogenesis. *Translational Medicine*. 10: 8-12.
- Pisanti S., Malftano AM., Ciaglia E., Lamberti A., Ranieri R., Cuomo G., Abate M., Faggiana G., Proto MC., Fiore D., Laezza C. and Bifulco M. (2017). Cannabidiol:

state of the art and new challenges for therapeutic applications. *Pharmacol Ther* 175:133–150

- Pisters P.W., R.E. Pollock, V.O. Lewis, A.W. Yasko, J.N. Cormier, P.M. Respondek, B.W. Feig, K.K. Hunt, P.P. Lin, G. Zagars, C. Wei, and M.T. Ballo (2007). Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 41 extremity and trunk soft tissue sarcomas. *Ann Surg.*, 246(4):675-681
- Preet A., R.K. Ganju, and J.E. Groopman (2008). Delta9-Tetrahydrocannabinol Inhibits Epithelial Growth Factor-Induced Lung Cancer Cell Migration in Vitro as Well as Its Growth and Metastasis in Vivo. *Oncogene*. 27(3): 339-346.
- Qamri Z, Preet A, Nasser MW, Bass CE, Leone G, Barsky SH, (2009). Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. *Molecular cancer therapeutics* 8(11): 3117-3129.
- Ramos JA, Bianco FJ (2012). The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications. *Indian J Urol*, 28(1): 9–14.
- Ramadori G., Lenzi M., Dienes H .P. and Büschensfelde K .H. (1983). Binding properties of mechanically and enzymatically isolated hepatocytes for IgG and C3. *Liver*, 3(6): 358-368.
- Ramer R. and Hinz B. (2016). Antitumorigenic Targets of Cannabinoids - Current Status and Implications. *Expert Opin Ther Targets*. 20(10): 1219-35.
- Ramer R., Heinemann K., Merkord J., Rohde H., Salamon A., Linnebacher M., and Hinz B. (2013). COX- 2 and PPAR- γ confer cannabidiolinduced apoptosis of human lung cancer cells. *Mol Cancer Ther*, 12(1): 69–82.
- Ramer R. (2014). Cannabinoids Inhibit Angiogenic Capacities of Endothelial Cells Via Release of Tissue Inhibitor of Matrix Metalloproteinases-1 from Lung Cancer Cells. *Biochem Pharmacol*. 91(2): 202-16.
- Ranganathan M. and D'Souza DC (2006). The acute effects of cannabinoids on memory in humans: a review. *Psychopharmacology* 188: 425–444.
- Raty J., Pikkarainen J., Wirth T., and Yla-Herttuala S. (2008). “Gene therapy: the first approved gene-based medicines, molecular mechanisms and clinical indications,” *Current Molecular Pharmacology*, 1(1):13–23.
- Restifo NP (1993). Identification of human cancers deficient in antigen processing. *J. Exp. Med* 177, 265–272.

- Remondo C., Cereda V., and Mostböck S. (2009). "Human den-dritic cell maturation and activation by a heat-killed recombi-nant yeast (*Saccharomyces cerevisiae*) vector encoding carcinoembryonic antigen," *Vaccine*, 27(7): 987–994.
- Romano B., Borrelli F., Pagano E., Cascio MG., Pertwee RG. and Izzo AA. (2014). Inhibition of colon carcinogenesis by a standardized *Cannabis sativa* extract with high content of cannabidiol. *Phytomedicine*. 21:631– 9.
- Reekie T. A., Scott, M. P. and Kassiou, M. 2017. The evolving science of phytocannabinoids. *Nature Reviews Chemistry*, 2, 0101.
- Ries L.A.G., M.A. Smith, J.G. Gurney, M. Linet, T. Tamra, J.L. Young, and G.R. Bunin, eds. (1999). *Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995.*, National Cancer Institute, 2: 211-287.
- Rinaa S Punglia, Akiko M Saito, Bridget A Neville, Craig C Earle and Jane C Weeks (2010). *BMJ*; 340: 845.
- Russo E.B. (2011). Taming Thc: Potential Cannabis Synergy and Phytocannabinoid-Terpenoid Entourage Effects. *Br j Pharmacol*, 163(7): 1344-64.
- Russo EB, (2019). The case for the entourage effect and conventional breeding of clinical cannabis: no "strain," no gain. *Front Plant Sci*. 9:1– 8
- Russo E and Guy GW (2006). A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. *Med Hypotheses* 66: 234–246.
- Rosalia R. A., Quakkelaar E. D. and Redeker A. (2013). "Dendritic cells process synthetic long peptides better than whole pro-teín, improving antigen presentation and T-cell activation," *European Journal of Immunology*, 43, (10): 2554–2565.
- Salgia R., Lynch T., Skarin A. (2003). "Vaccination with irradi- ated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor aug-ments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma," *Journal of Clinical Oncology*, 21(4): 624–630.
- Salazar M. (2009). Cannabinoid Action Induces Autophagy-Mediated Cell Death through Stimulation of Er Stress in Human Glioma Cells. 119(5): 1359-72.
- Santos E.W., Oliveira D.C.D., Hastreiter A., Silva G.B.D., Beltran J.S.D.O., Tsujita M., Crisma A.R., Neves S.M.P., (2016). Hematological and biochemical references values for C57BL/6, Swiss Webster and BALB/c mice, *Brazilian Journal of Veterinary Research and Animal Science*, 53, 138- 145.
- Sarfaraz S., Adhami, V. M., Syed, D. N., Afaq, F. & Mukhtar, H. (2008). Cannabinoids for Cancer Treatment: Progress and Promise. *Cancer Research*, 68, 339-342.

- Sartim AG, Guimaraes FS, Joca SR (2016). Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex-possible involvement of 5-HT1A and CB1 receptors. *Behav Brain Res.*, 303: 218–227.
- Sarker SD, Nahar L. (2012). *Natural Products Isolation*, 3rd Edition, Humana Press – springerVerlag, New Jersey.102, 322-389
- Santavy F. (1964). Notes on the structure of cannabidiol compounds. *Acta Univ Olomuc Fac Med.* 35, 5–9.
- Schultes RE, Klein WM, Plowman T, Lockwood TE (1974). Cannabis: an example of taxonomic neglect. *Harvard University Botanical Museum Leaflets* 23:337–367.
- Scherer HJ (1938). Structural development in gliomas. *Am J Cancer.*, 34(3):333–351.
- Schulof R. S., Mai D., Nelson M. A. (1988). “Active specific immunotherapy with an autologous tumor cell vaccine in patients with resected non-small cell lung cancer,” *Molecular Biotherapy*, 1(1): 30–36.
- Scarlett KA, White EZ, Coke CJ, Carter JR, Bryant LK, Hinton CV (2018). Agonist-induced CXCR4 and CB2 heterodimerization inhibits Gα13/RhoA-mediated migration. *Mol Cancer Res* 16(4):728–739.
- Scott K.A., Dalgleish A.G., and Liu W.M. (2014). The Combination of Cannabidiol and Delta9-Tetrahydrocannabinol Enhances the Anticancer Effects of Radiation in an Orthotopic Murine Glioma Model. *Mol Cancer Ther*, 13(12): 2955-67.
- Seitz H. K., Poschl G., Simannowski U.A. (1998). Alcohol and cancer. *Recent Dev .Alcohol*, 14: 67 – 95.
- Stern CA, Gazarini L, Takahashi RN, Guimaraes FS, Bertoglio LJ (2012). On disruption of fear memory by reconsolidation blockade: evidence from cannabidiol treatment. *Neuropsychopharmacology* 37: 2132–2142.
- Stewart H.L., Snell K.C., Dunham L.J. (1959). *National Academy of Sciences-National Research Council*, Washington DC, 317-324.
- Singh K, Nassar N, Bachari A, Schanknecht E, Telukutla S, Zomer R, Piva TJ, Mantri N (2021). The pathophysiology and the therapeutic potential of cannabinoids in prostate cancer. *Cancers* 13:4107.
- Simons J. W. (2006). “Phase I/II trial of an allogeneic cellular immuno-therapy in Hormone-Naive prostate cancer,” *Clinical Cancer Research*,12(11):3394–3401.
- Soini G, Sanchez C, Guzman M (1998). Towards the use of cannabinoids as antitumour agents. *Nat Rev Cancer*, 20(12): 565-584.

- Shen J, Zhou S, Shi L, Liu X, Lin H, Yu H, Liang X, Tang J, Yu T, Cai X (2017). DUSP1 inhibits cell proliferation, metastasis and invasion and angiogenesis in gallbladder cancer. *Oncotarget* 8:12133–12144
- Shrivastava A. (2011). Cannabidiol Induces Programmed Cell Death in Breast Cancer Cells by Coordinating the Cross-Talk between Apoptosis and Autophagy. *10*(7): 1161-72.
- Shrivastava A, Kuzontkoski PM, Groopman JE, Prasad A (2011). Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. *Mol Cancer Ther* 10(7):1161–1172.
- Shammari E. C., and Ravichandran K. S. (2016). A Systems Perspective of Ras Signaling in Cancer. *Clinical Cancer Research*, 15: 1510-1513.
- Small E. J., Fratesi P., Reese D. M. (2000). “Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells,” *Journal of Clinical Oncology*, 18(23):3894–3903.
- Siegel S and Giannetta C. (2019). Optimizing management of neutropenia and anemia in cancer chemotherapy. *Hematol.* 48: 39–S47.
- Sinha R., Peters, U . and Cross, A. J. (2005) : Meat cooking methods and preservation , and Risk of colorectal adenoma . *Cancer Res*, 65: 8034 – 8041.
- Steele R.W. (2012). Managing Infection in Cancer Patients and Other Immunocompromised Children. *Ochsner Journal*; 12(3): 202–210.
- Stellman SD, Resnicow K (1997). Tobacco smoking,cancer and social class. *Social Inequalities and Cancer*, (IARC Scientific Publications, No. 138), Press, 229-250.
- Steinman R. M. and Banchereau J. (2007). “Taking dendritic cells into medicine,” *Nature*, 449(7161): 419–426.
- Su MC, Cheng CY, Wang PC. (2014). A neural-network-based approach to white blood cell classification. *Scientific World Journal*, 23:796-827.
- Sundaram M., Patra S., and Maniarasu G. (2012): Antitumor activity of ethanol extract of *Gracilaria edulis* (Gmelin) Silva on Ehrlich ascites carcinoma-bearing mice. *Journal of Chinese Integrative Medicine*, 10: 21-229.
- Tani K., Azuma M., Nakazaki Y. (2004). “Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: clinical and immunological findings,” *Molecular Therapy*,10(4): 799–816.

- Taha T, Meiri D, Talhamy S, Wollner M, Peer A, BarSela G. (2019). Cannabis impacts tumor response rate to nivolumab in patients with advanced malignancies. *Oncologist*. 24:549–54.
- Takeda, S. (2012). Cannabidiolic Acid, a Major Cannabinoid in Fiber-Type Cannabis, Is an Inhibitor of Mda-Mb-231 Breast Cancer Cell Migration. *Toxicol Lett*. 214(3): 314-9
- Taskin E. (2008). Ehrlich Ascites Tümörü ile Balb-C Farelerde Oluşturulmuş Solid Tümör Modelinde Curcuminin Apoptoz Üzerine Etkileri. *İstanbul Üniversitesi Sağlık Bilimleri Enstitüsü Tıbbi Biyoloji Anabilim Dalı. İstanbul. Med.*, 66:96-107.
- Tesfay S. Z., Bertling I., and Bower J. P. (2012). D-Mannoheptulose and perseitol in ‘Hass’ avocado: metabolism in seed and mesocarp tissue. *South African Journal of Botany*, 79: 159-165.
- Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG (2007). Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. *Br J Pharmacol*, 150: 613–623.
- Tran P. T., Fan A. C., Bendapudi P. K., Felsher, D.W. (2008). Combined Inactivation of MYC and K-Ras Oncogenes Reverses Tumorigenesis in Lung Adenocarcinomas and Lymphomas. *Plos One*, 3(5): 1-12.
- Tomko A.M. (2020). Anti-Cancer Potential of Cannabinoids, Terpenes, and Flavonoids Present in Cannabis. *Cancers*, 12(7): 21-88.
- Torre C. L., Morrow M. P., Kraynyak K. A. (2015). “Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial,” *Lancet*, 386(10008): 2078–2088.
- Torres S. (2011). A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma. *Mol Cancer Ther.*, 10(1): 90-103.
- Torgovnick A, Schumacher B. (2015). DNA repair mechanisms in cancer development and therapy. *Front Genet.*, 6: 157.
- Tsoi L. C., Wolf B., and Chen Y. A. (2017). “The promise of genomic studies on human diseases: from basic science to clinical application,” *International Journal of Genomics*, 79(8): 22-50.
- Uddin AK, Khan ZJ, Islam J, Mahmud AM (2013). Cancer care scenario in Bangladesh. *South Asian J Cancer*; 2:102-4.

- Vandin F, Upfal E, Raphael BJ. (2012). De novo discovery of mutated driver pathways in cancer. *Genome Res.* 22 (2): 375–85.
- Verheul H. M. W., Hoekman K., Jorna A. S., Smit E. F. and Pinedo H. M. (2000). The *Oncologist* 5: 45–50.
- Velasco G, Sanchez C, Guzman M (2012). Towards the use of cannabinoids as antitumour agents. *Nat Rev Cancer* 12(6): 436-444.
- Wang L. H., Wu C. F., Rajasekaran, N., and Shin Y. K. (2018). Loss of Tumor Suppressor Gene Function in Human Cancer: An Overview. *Cellular Physiology and Biochemistry*, 51(6): 2647-2693.
- Wansley E. K., M. Chakraborty, K. W. Hance (2008). “Vaccination with a recombinant *Saccharomyces cerevisiae* expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses,” *Clinical Cancer Research*, vol. 14, no. 13, pp. 4316–4325.
- Ward E., P. Boffetta, A. Andersen, D. Colin, P. Comba, J.A. Deddens, M. De Santis, G. Engholm, L. Hagmar, S. Langard, I. Lundberg, D. McElvenny, R. Pirastu, D. Sali, and L. Simonato (2001). Update of the follow-up of mortality and cancer incidence among European workers employed in the vinyl chloride industry. *Epidemiology*, 12(6): p. 710-8.
- Wang C, Weindruch R, Fernández JR, Coffey CS, Patel P, Allison DB. (2004). Caloric restriction and body weight independently affect longevity in Wistar rats. *Int J Obes Relat Metab Disord.*;28:357-62.
- Wang C, Chen YG, Gao JL, Lyu GY, Su J, Zhang QI, Ji X, Yan JZ, Qiu QL, Zhang YL (2015). Low local blood perfusion, high white blood cell and high platelet count are associated with primary tumor growth and lung metastasis in a 4T1 mouse breast cancer metastasis model. *Oncol Lett* 10: 754-760.
- Weide B., Carralot P., and Reese A. (2008). “Results of the first phase I/II clinical vaccination trial with direct injection of mRNA,” *Journal of Immunotherapy*, 31(2):180–188.
- Weide B., Pascolo S. and Scheel B. (2009). “Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients,” *Journal of Immunotherapy*, 32(5): 498–507.
- Weissmueller S, Manchado E, Saborowski M, Morris JP, Wagenblast E, Davis CA (2014). Mutant p53 drives pancreatic cancer metastasis through cell–autonomous PDGF receptor β signaling. *Cell*. 157 (2): 382– 94.

- Wu H, Gao L, Li F, Song F, Yang X, Kasabov N. (2015). Identifying overlapping mutated driver pathways by constructing gene networks in cancer. *BMC Bioinformatics*. 16 (Suppl 5): S3.
- White MK, Pagano JS, Khalili K. (2014). Viruses and human cancers: a long road of discovery of molecular paradigms. *Clin Microbiol Rev*. 27 (3): 463–81.
- WHO. (2022). International Agency for Research on Cancer. Estimated number of deaths in (2020), all cancers, both sexes, all ages. Cancer today. Published 2020. Accessed January 14,2022.
- WHO. (2022). International Agency for Research on Cancer. Estimated number of new cases from 2020 to 2040, Incidence, Both sexes, age [0-85+]. Published 2020. Accessed January14, 2022.
- WHO. (2014). Noncommunicable Diseases (NCD) Country Profiles: Bangladesh. Geneva: World Health Organization.
- Wroblewski F, Ladue JS. (1956). Serum glutamic pyruvic transaminase in cardiac with hepatic disease. *Proc Soc Exp Biol Med*;91:569-71
- World: Drug Report 2019. Vienna, Austria: United Nations; 2019.
- Wang X., Zuo D., Sarkar D., and Fisher P. B. (2011). “Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma,” *Expert Opinion on Phar-macotherapy*, 12(17): 2695–2706.
- Xue LB, Liu YH, Zhang B (2019). Prognostic role of high neutrophil to lymphocyte ratio in breast cancer patients receiving neoadjuvant chemotherapy: meta-analysis. *Medicine (Baltimore)*. 98(1): 13842.
- Yarbro CH, Wujcik, D, Gobel BH (2011). *Oncology Nursing Review* (5th Edition), Jones and Bartlett Publishers, Sudbury. 98-100
- Yan Y., Kumar A. B., Finnes H. (2018). “Combining immune checkpoint inhibitors with conventional cancer therapy,” *Frontiers in Immunology*, 9(1): 5–21.
- Zeybek ŞÜ (1996). En Uygun Ehrlich Ascites Tümör Modellerinin Farklı Soy ve Cinsiyetteki Farelerde Gösterilmesi. İstanbul Üniversitesi Sağlık Bilimleri Enstitüsü Deney Hayvanları Biyolojisi ve Biyomedikal Uygulama Teknikleri Anabilim Dalı. Yüksek Lisans Tezi. İstanbul. 4(2): 15–20.
- Zou W. (2005). “Immunosuppressive networks in the tumour environment and their therapeutic relevance,” *Nature Reviews Cancer*, 5(4): 263–274.